课题基金 / 基金详情

TAXOTERE W/ CONTINUOUS INFUSION TOPOTECAN IN ADVANCED MALIGNANCIES

TAXOTERE W/ CONTINUOUS INFUSION TOPOTECAN IN ADVANCED MALIGNANCIES
泰索帝联合拓扑替康持续输注治疗晚期恶性肿瘤
批准号:
6263456
负责人:
James A Posey
金额:
$2.95万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

James A Posey的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Taxotere and Topotecan are relatively new drugs that have proven anti-cancer activity. Both agents poison and ultimately irreversibly damage some types of cancer cells. The purpose of this research is to determine in patients whether the two agents can be given safely together. While we will be watching for decreasing size of the tumor, the primary focus of this study is to determine if these agents can be given together effectively. Patients will be assigned to an arm and dose level which will determine the amount of drug and the order of receiving the agents. The first treatment will be given in the hospital over approximately 4 days. Additional treatments, if well tolerated, will be given as an outpatient. Taxotere is given through a vein over an hour. Topetecan will be given continuously over 72 hours. The treatment will be repeated in 21 days. If the treatment is well tolerated, patients may receive a maximum of six treatments. If T&T treatment is discontinued for any reason, we will follow these patients for another month to assess possbility of delayed side effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UAB 0282 GEMCITABINE
Rebeccamycin in hepatabiliary cancers
TAXOTERE W/ CONTINUOUS INFUSION TOPOTECAN IN ADVANCED MALIGNANCIES
PNU 214936 IN ADVANCED ADENOCARCINOMAS OF THE BREAST
海外基金